ReportRisk Alleles Associated with Neovascularization in a Pachychoroid Phenotype
References (5)
- et al.
Optical coherence tomography angiography of shallow irregular pigment epithelial detachments in pachychoroid spectrum disease
Am J Ophthalmol
(2015) - et al.
Heritability and genome-wide association study to assess genetic differences between advanced age-related macular degeneration subtypes
Ophthalmology
(2012)
Cited by (30)
Central serous chorioretinopathy: An update on risk factors, pathophysiology and imaging modalities
2020, Progress in Retinal and Eye ResearchCitation Excerpt :Even though these two entail formation of macular neovascularization they differ from neovascular AMD, both in terms of aetiology and thereby in their management strategies. Moreover, even though patients with AMD and those with pachychoroid neovascularization have been found to have similar genetic profiles with respect to established AMD risk alleles, their frequencies were very low and similar in non-neovascular and neovascular pachychoroid phenotypes (Dansingani et al., 2016b). Focal choroidal excavation (Fig. 13) is defined as a local idiopathic depression in the choroid in patients lacking any systemic cause for choroidal thinning (Obata et al., 2013).
Pachychoroid disease
2019, Central Serous ChorioretinopathyTwenty-four-month real-life treatment outcomes of polypoidal choroidal vasculopathy versus type 1 macular neovascularization in Caucasians
2023, Clinical and Experimental OphthalmologyDilated choroidal vascular channels in pachychoroid neovasculopathy
2023, Clinical and Experimental OphthalmologyResearch progress in choroidal neovascularization secondary to central serous chorioretinopathy
2022, Recent Advances in Ophthalmology
Financial Disclosure(s): The author(s) have made the following disclosure(s): L.T.P. and S.H.: Employed by Regeneron Inc., with stock options.
R.F.S.: Consultant – Bausch & Lomb and Topcon Corp. (Tokyo, Japan); Royalty fees – Topcon.
J.M.K.: Consultant – Bayer HealthCare.
L.A.Y.: Support – Genentech have funded an educational program on retinal disease.
M.J.C.: Consultant – Bausch & Lomb, Speaker – Genentech, and holds equity in Ohr Pharmaceuticals.
M.E.: Consultant – Bayer HealthCare and Genentech.
K.B.F.: Consultant – Genentech, Bayer HealthCare, Optovue, Heidelberg Engineering, and Optos.
The LuEsther T. Mertz Retinal Research Center and the Macula Foundation Inc., New York, New York, supported this research but had no role in the design or conduct of the study or the decision to publish.
Author Contributions:
Conception and design: Perlee, Hamon, Lee, Shah, Chen, Hewitt, Freund
Data collection: Dansingani, Lee, Shah, Spaide, Sorenson, Klancnik, Yannuzzi, Barbazetto, Cooney, Engelbert, Freund
Analysis and interpretation: Dansingani, Perlee, Hamon, Freund
Obtained funding: Not applicable
Overall responsibility: Dansingani, Perlee, Hamon, Lee, Shah, Spaide, Sorenson, Klancnik, Yannuzzi, Barbazetto, Cooney, Engelbert, Chen, Hewitt, Freund